Valion Bio
VBIO----
Valion Bio (VBIO)
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to t...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
News
- benzinga_article · Jul 24 at 04:05 PM
12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga_article · Jul 20 at 07:05 AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
- StockTitan · Jul 20 at 04:28 AM
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market | VBIO Stock News
- benzinga_article · Jul 14 at 12:05 PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
- prnewswire · Jul 14 at 06:46 AM
07:45 ETValion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
- Price Alert · Jul 13 at 01:07 PM
U.S. stock market midday update: Valion Bio down 11.59%, volume increased, sector volatility intensified
